Interferon-combination strategies for the treatment of chronic hepatitis C

Seminars in Liver Disease

Volumn 34, Issue 1, 2014, Pages 30-36

  Aronsohn, Andrew ^a   Jensen, Donald ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

direct acting antiviral agents; hepatitis C; hepatitis C therapy

Indexed keywords

ASUNAPREVIR; DACLATASVIR; DANOPREVIR; DELEOBUVIR; FALDAPREVIR; INTERFERON; LOMIBUVIR; MERICITABINE; MK 5172; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; UNCLASSIFIED DRUG; VEDROPREVIR; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CATALYSIS; GENOTYPE; HEPATITIS C; HUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RNA REPLICATION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MOLECULAR TARGETED THERAPY; PROTEASE INHIBITORS; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84899659033     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1371008     Document Type: Article

References (41)

1. Jacobson I. M., McHutchison J. G., Dusheiko G., et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med: 2011; 364 25 2405 2416
2. Poordad F., McCone J. Jr, Bacon B. R., et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1195 1206
3. Di Bisceglie A., Kuo A., Rustgi V., Sulkowski M. Virological outcomes and adherence to treatment algorithms in a longitudinal study of patients with chronic hepatitis C treated with boceprevir or telaprevir in the U.S. (HCV-TARGET). Paper presented at: AASLD The Liver Meeting; November 1-5, 2013; Washington, DC
4. Brass V., Berke J. M., Montserret R., Blum H. E., Penin F., Moradpour D. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci U S A: 2008; 105 38 14545 14550
5. Loo Y. M., Owen D. M., Li K., et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A: 2006; 103 15 6001 6006
6. Clark V. C., Peter J. A., Nelson D. R. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int: 2013; 33 01 80 84
7. Jacobson I., Dore G., Foster G., Fried M. Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a Phase III trial. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24-28, 2013; Amsterdam, The Netherlands
8. Olysio. Available at: http:www:olysio.com. Accessed February 9, 2014
9. Manns M., Marcellin P., Poordad F., Addonso de Araujo E. Simeprevir (TMC435) with peginterferon-α2a or -α2b and ribavirin in treatment-naïve HCV genotype 1 patients: QUEST-2, a randomised phase III trial. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24-28, 2013; Amsterdam, The Netherlands
10. Zeuzem S., Berg T., Gane E., et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb trial. Gastroenterology: 2014; 146 2 430, e6
11. Summa V., Ludmerer S. W., McCauley J. A., et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother: 2012; 56 8 4161 4167
12. Manns M., Vierling J., Bacon B., Marcellin P. High sustained viral response of MK-5172 with pegylated interferon alfa-2b and ribavirin in HCV genotype 1 treatment-naive non-cirrhotic patients. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24-28, 2013; Amsterdam, The Netherlands
13. Bronowicki J. P., Pol S., Thuluvath P. J., et al. Randomized study of asunaprevir plus pegylated interferon-. α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther: 2013; 18 7 885 893
14. Bronowicki J. P., Ratziu V., Gadano A., Thuluvath P. J. Asunaprevir with peginterferon-alfa and ribavirin in treatment-naive patients with genotype-1 or -4 chronic hepatitis C: SVR24 results from a randomized phase 2b study (AI447-016). Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24-28, 2013; Amsterdam, The Netherlands
15. Sulkowski M. S., Asselah T., Lalezari J., et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology: 2013; 57 6 2143 2154
16. Sulkowski M. S., Bourlière M., Bronowicki J. P., et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology: 2013; 57 6 2155 2163
17. Jensen D., Asselah T. D.. D., Foster GR. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C genotype-1 infection. Paper presented at: AASLD The Liver Meeting; November 1-5, 2013; Washington, DC
18. Jacobson I., Asselah T., Ferenci P., Foster G. STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. Paper presented at: AASLD The Liver Meeting; November 1-5, 2013; Washington, DC
19. Rockstroh J., Nelson M., Soriano V., Arasteh K. STARTVerso 4 Phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response. Paper presented at: AASLD The Liver Meeting; November 1-5, 2013; Washington, DC
20. Lee C. Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther: 2013; 7 1223 1233
21. Gao M., Nettles R. E., Belema M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature: 2010; 465 7294 96 100
22. Dore G., Lawitz E., Hezode C., Shafran S. D. Daclatasvir combined with Peginterferon Alfa 2a Alfa-and Ribavirin for 12 or 16 Weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 study. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24-28, 2013; Amsterdam, The Netherlands
23. Hezode C., Hirschfield G. M., Ghesquiere W., Sievert W. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2b COMMAND-1 SVR12 results. Paper presented at: AASLD The Liver Meeting; November 9-13, 2012; Boston, MA
24. Au J. S., Pockros P. J. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther: 2013; 95 1 78 88
25. Lawitz E., Rodriquez-Torres M., Rustgi V., Hassanein T. Safety and antiviral activity of ANA598 in combination with pegylated interferon α2a plus ribavirin in treatment-naïve genotype-1 chronic HCV patients. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24-28, 2013; Amsterdam, The Netherlands
26. Available at: A study of setrobuvir in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in patients with genotype 1 chronic hepatitis C. Available at: www.clinicaltrials.gov. Accessed December 27, 2013
27. Zeuzem S., Soriano V., Asselah T., et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med: 2013; 369 7 630 639
28. Larrey D., Lohse A. W., de Ledinghen V., et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol: 2012; 57 1 39 46
29. Kowdley K. V., Lawitz E., Crespo I., et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet: 2013; 381 9883 2100 2107
30. Lawitz E., Lalezari J. P., Hassanein T., et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis: 2013; 13 5 401 408
31. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med: 2013; 368 20 1878 1887
32. Wedemeyer H., Jensen D., Herring R. Jr., et al. PROPEL Investigators. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology: 2013; 58 2 524 537
33. Pockros P. J., Jensen D., Tsai N., et al. JUMP-C Investigators. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology: 2013; 58 2 514 523
34. Feld J., Jacobson I., Jensen D., Foster G. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Paper presented at: AASLD The Liver Meeting; November 9-13, 2012; Boston, MA
35. ClinicalTrials.gov. A study of mericitabine in combination with telaprevir and Pegasys/Copegus in patients with chronic hepatitis C. Available at: http://clinicaltrials.gov/ct2/show/NCT01482390?term=mericitabine&rank=1. Accessed February 9, 2014
36. ClinicalTrials.gov. A study of mericitabine in combination with boceprevir and Pegasys/Copegus in patients with chronic hepatitis C. Available at: http://clinicaltrials.gov/ct2/show/NCT01482403?term=mericitabine&rank=2. Accessed February 9, 2014
37. Lok A. S., Gardiner D. F., Lawitz E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med: 2012; 366 3 216 224
38. Lok A. S., Hezode C., Lawitz E., Gardiner D. F. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Paper presented at: AASLD The Liver Meeting; November 9-13, 2012; Boston, MA
39. Gane E., Di Bisceglie A., Sulkowski M., Jacobson I. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. Paper presented at: The 22st Conference of the Asian Pacific Association for the Study of the Liver APASL February 16-19, 2012; Taipei, Taiwan
40. Zeuzem S., Buggisch P., Agarwal K., et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology: 2012; 55 3 749 758
41. Pol S., Jablkowski M., Trenkle J., Kanwar B. Antiviral efficacy of the once daily NS3 protease inhibitor GS-9451, the non-nucleoside NS5B inhibitor tegobuvir (GS-9190), and pegylated interferonb